Drug Trial Radar · NCT01697384
Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jan 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Apr 2000
Primary completion
Aug 2003
Study completion Oct 2004
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective was to evaluate the efficacy and safety of the histrelin acetate subdermal implant (originally versus Lupron Depot-3 Month) in male patients with advanced prostate cancer during 52 weeks of treatment with the implant. After consultation w/ FDA, design was modified to eliminate the Lupron arm and continued the study as an open-label non-randomized study. Primary endpoint was testosterone suppression, as assessed by the percent of patients whose testosterone indicated chemical castration levels (\<=50 ng/dL) through 52 weeks of treatment with an implant.
Conditions
- Prostate Cancer
- Adenocarcinoma of the Prostate
Interventions
histrelin acetateDrug
52 week implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Suppression of testosterone to chemical castration levels (<= 50 ng/dL)Time frame: 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.